The study forms part of the Chennai Urban Rural Epidemiology Study, one of the largest systematic epidemiological efforts focused on urban and peri-urban populations in southern India, a region where the burden of type 2 diabetes and cardiometabolic disease has risen sharply over recent decades. Asian Indian populations are known to experience cardiometabolic disorders at lower body weights and younger ages than many other groups, making the identification of modifiable factors that interact with inherited risk a priority for prevention strategies in the subcontinent and among diaspora communities worldwide.

To quantify inherited susceptibility, the researchers constructed a genetic risk score based on three single nucleotide polymorphisms, the single-letter DNA variations that are among the most common forms of human genetic difference. Each participant was assigned a score reflecting the number of risk alleles they carried, the specific variant forms of these genes that have been associated with adverse lipid profiles. Individuals carrying more than one risk allele were classified into a high genetic risk group, while those with one or fewer were placed in the low genetic risk group. This approach, though simpler than the polygenic scores now common in large European biobank studies, is well suited to smaller, deeply phenotyped cohort studies and captures a meaningful slice of the heritable component of cholesterol variation.

Diet quality was assessed using a diet quality score, a composite measure that summarizes overall dietary patterns rather than focusing on any single nutrient or food item. Participants were divided into three categories: those with low diet quality scores below 68.65, those in the medium range between 68.66 and 87.87, and those with high scores above 87.88. This stratification allowed the investigators to test a central question of modern nutritional genetics, namely whether the environment, in this case what people eat, modifies the degree to which their genes influence a clinically important trait.

The results were striking in their specificity. Among participants with low diet quality scores, the researchers observed a significant difference in mean log-transformed serum total cholesterol between the high and low genetic risk groups, with a statistical significance level of p less than 0.001. In other words, when diets were poor, genetic predisposition appeared to assert itself, and individuals carrying more than one risk allele had markedly higher cholesterol than their genetically lower-risk counterparts. Yet among those eating medium- or high-quality diets, this genetic difference essentially vanished, with p values of 0.521 and 0.621 respectively, indicating no detectable difference in cholesterol between genetic risk groups at those diet quality levels.

Perhaps most compelling was the formal statistical test of interaction between diet quality and genetic risk, which yielded a p value of 0.003. In epidemiological terms, an interaction of this kind means that the effect of one factor on an outcome depends on the level of another. Here, the effect of the genetic risk score on serum total cholesterol depended on diet quality: genes mattered most when diets were worst. This pattern is consistent with the concept of gene-environment interaction, a cornerstone of contemporary chronic disease research, and it implies that diet is not merely an independent risk factor but a potential amplifier or damper of inherited lipid risk.

Serum total cholesterol is a critical variable in this context because elevated levels are a major modifiable driver of atherosclerosis, the process by which fatty plaques accumulate in artery walls and eventually precipitate heart attacks and ischemic strokes. Cholesterol is also tightly linked to metabolic syndrome and type 2 diabetes, conditions to which Asian Indian populations show pronounced vulnerability. Dyslipidemia, the clinical term for abnormal blood lipid levels, frequently co-occurs with insulin resistance in these populations and contributes to the elevated cardiovascular mortality observed among people of South Asian descent both in India and abroad.

The findings carry practical weight because diet quality is modifiable in a way that genes are not. If a poor diet permits genetic predisposition to express itself as elevated cholesterol, then improving dietary patterns could, in principle, blunt the impact of inherited risk. The study’s data suggest that the protective association of higher diet quality was observed regardless of genetic risk category, since no significant cholesterol differences between genetic groups remained at medium and high diet quality levels. While the observational design of the study means that causality cannot be definitively established, the interaction pattern provides a biological and statistical rationale for prioritizing dietary improvement among genetically susceptible individuals.

The research also addresses a long-standing gap in nutritional genomics. Much of the landmark work on gene-diet interaction in cardiovascular risk has been conducted in European and North American cohorts, and risk scores and dietary instruments developed in those settings do not always transfer cleanly to South Asian populations, whose dietary patterns, genetic architecture and body composition differ in important ways. By analyzing a Chennai-based cohort with tools calibrated to that population, the study contributes to a more globally representative evidence base. The authors represent institutions in the United Kingdom, Saudi Arabia and India, reflecting the international collaboration increasingly required to study cardiometabolic disease in transitioning economies.

The work was supported in part by the British Nutrition Foundation, with a scholarship from the Ministry of Higher Education of Saudi Arabia awarded to the first author. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript, and the authors declared no competing interests. The study is published in PLOS One under DOI 10.1371/journal.pone.0357182, and the underlying data derive from the CURES cohort, which has previously yielded insights into diabetes prevalence, vascular complications and metabolic risk factors in urban South India.

For clinicians and public health authorities, the message is one of targeted prevention. Genetic testing for common lipid-related variants remains far from routine in most clinical settings, and the three-SNP score used here captures only part of the inherited contribution to cholesterol. Nevertheless, the study reinforces a broader principle that has emerged from population health research: genetic risk is not destiny, and the expression of inherited susceptibility often depends on the environment in which it is embedded. In Chennai, as in many rapidly urbanizing populations, the dietary transition toward refined carbohydrates, fried foods and energy-dense processed items may be quietly compounding the genetic cards that individuals were dealt, while improvements in overall diet quality could help keep that inherited risk in check. As cardiometabolic disease continues to climb across South Asia, evidence that diet quality can mask or unmask genetic predisposition to high cholesterol offers a concrete, actionable lever for reducing the region’s disproportionate burden of diabetes, stroke and heart attack.

Subject of Research: Gene-diet interaction effects on serum cholesterol and cardiometabolic risk in Asian Indian adults

Article Title: A poor-quality diet might exacerbate the effect of genetic predisposition to diabetes, stroke and heart attack in Asian Indian populations, per study of 1,020 men and women from Chennai.

Article References: A poor-quality diet might exacerbate the effect of genetic predisposition to diabetes, stroke and heart attack in Asian Indian populations, per study of 1,020 men and women from Chennai.. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: genetic risk score, diet quality, serum cholesterol, Asian Indian population, cardiovascular disease, type 2 diabetes, gene-environment interaction, Chennai, PLOS One, dyslipidemia, nutrition, epidemiology

The type 1 diabetes genetic risk score, or T1D-GRS, is a tool that has already proven its worth in diabetes prediction and classification. It aggregates information from ten single nucleotide polymorphisms, or SNPs—individual positions in the genome where the DNA letter varies between people and where certain variants shift the probability of developing the autoimmune form of diabetes. Because the score draws on genetic variants that remain stable throughout life, it can help distinguish type 1 from type 2 diabetes in young adults and identify individuals at elevated risk long before symptoms appear. Crucially, the T1D-GRS and islet autoantibodies, the immune markers that signal the body’s attack on insulin-producing cells, act as independent predictors of diabetes, which makes pairing them particularly powerful for screening and diagnostic purposes.

The obstacle has always been practical rather than scientific. To calculate the score, laboratories traditionally need genomic DNA extracted from white blood cells, which involves purification, quantification and storage steps that add expense at every turn, before a single genotyping reaction has even been set up. The Exeter team reasoned that this entire pipeline might be unnecessary. Serum, the very material already used for islet autoantibody assays, contains extracellular DNA released from cells that burst during the clotting process. If that DNA were sufficient for genotyping, the same tube of blood could serve both the antibody test and the genetic score, eliminating the need for a separate DNA extraction altogether.

There was a catch, however, and it lay in the biochemistry of clotting. The extracellular DNA in serum comes from leukocytes that rupture as the blood clots, so the amount of genomic DNA available depends on how long the sample is allowed to clot before being spun down in a centrifuge. Many standard serum processing protocols specify clotting times of less than thirty minutes, a window that previous work suggested may be inadequate for releasing enough genomic DNA into the fluid. The researchers therefore designed their study to answer two linked questions: whether a direct-from-serum genotyping method could calculate the ten-SNP T1D-GRS accurately, and how strongly the answer depended on clotting time.

The technical setup was deliberately conventional, which is part of the method’s appeal. The team used TaqMan SNP genotyping assays, a widely adopted fluorescence-based qPCR chemistry, together with TaqPath ProAmp Master Mix, in tiny five-microliter reactions containing just one microliter of either purified DNA or raw serum. Plates, prepared on a Biomek i7 Automated Workstation and run for fifty cycles on a QuantStudio 12K Flex Real-Time PCR System, included positive and no-template controls, and genotypes were called automatically using commercial software. In other words, nothing exotic was required—only standard reagents, standard instruments and a single microliter of serum per SNP.

Accuracy came first. In a cohort of 116 matched serum and whole-blood-derived DNA samples sent to the Exeter Genomics Laboratory from across the UK and Ireland, all with clotting times exceeding 24 hours, both biospecimens achieved call rates above 95 percent across all ten SNPs on the first pass, with no repeated reactions. A complete T1D-GRS was obtained from 84.5 percent of serum samples compared with 96.6 percent of purified DNA samples, a statistically significant difference, but among the 94 samples where both approaches yielded a complete score, the results agreed perfectly—100 percent concordance. In a subset of 32 samples with sequencing data available, the serum-derived scores were again fully concordant, confirming that the shortcut does not come at the cost of correctness.

The clotting-time experiment revealed where the method’s limits lie. The team analyzed 122 serum samples with recorded clotting times ranging from 12 to 475 minutes, running every sample in duplicate on separate qPCR runs to check reproducibility. Splitting the cohort at the thirty-minute mark produced a striking contrast. Samples clotted for thirty minutes or less achieved a genotyping success rate of just 68.8 percent, a replicate discordance rate of 28.8 percent, and yielded a complete ten-SNP score in only 7.4 percent of cases. Samples clotted for longer than thirty minutes, by comparison, reached a 97 percent genotyping success rate, only 2.2 percent replicate discordance, and complete scores in 77.8 percent of samples—a difference the authors report as highly significant. Performance in this longer-clotting group closely matched that of the samples clotted for more than 24 hours.

The explanation, the researchers argue, is straightforward: insufficient clotting time leaves too little extracellular DNA in the serum for reliable amplification. This aligns with earlier findings that PCR-based genotyping from samples containing very low DNA concentrations—below roughly 56 picograms—is unreliable. The practical message for laboratories hoping to combine genetic and biochemical testing is that serum should be allowed to clot for more than thirty minutes before processing, a duration that does not compromise autoantibody assays. Where additional tests sensitive to proteolysis, glycolysis or other degradation processes are needed, the authors suggest an intermediate clotting window of more than thirty minutes but under about three hours may offer the optimal balance between DNA release and analyte preservation.

The implications extend well beyond the immediate assay. A direct-from-serum approach could unlock cost-effective genotyping in the many large frozen serum biobanks around the world where no extracted DNA exists, allowing researchers to mine decades of stored samples for genetic risk information without retrieving new blood draws. Although the study tested only ten SNPs, the low input volume of one microliter per SNP suggests the same logic could scale to larger genotyping panels or alternative genotyping chemistries. For clinical laboratories that lack DNA-extraction capability, the proof-of-principle result points toward direct, automated assays that run antibody and genetic tests in parallel from a single serum sample. The work was supported by the National Institute for Health and Care Research Exeter Biomedical Research Centre, and the authors note existing research funding and licensing arrangements with Randox Laboratories to develop a T1D-GRS assay, underscoring the translational momentum behind the approach. If the method holds up in broader validation, the humble serum tube—already the workhorse of clinical chemistry—may become a one-stop source for both immune and genetic markers of diabetes risk.

Subject of Research: A direct-from-serum genotyping method for calculating a type 1 diabetes genetic risk score

Article Title: A direct-from-serum method for calculating a type 1 diabetes genetic risk score

Article References: Spurrier, B., Oram, R. A., Thomas, N. J., & Locke, J. M. (2026). A direct-from-serum method for calculating a type 1 diabetes genetic risk score. Journal of Translational Medicine, 24(1), Article 1148. https://doi.org/10.1186/s12967-026-08930-4

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08930-4

Keywords: type 1 diabetes, genetic risk score, serum, genotyping, TaqMan, qPCR, SNP, islet autoantibodies, DNA extraction, clotting time, biobanks, precision medicine

The scale and design of the study set it apart from most neuroimaging work in psychiatry. The team assembled resting-state functional MRI data from 657 patients with bipolar depression, of whom 405 were experiencing current suicidal thoughts and behaviors and 252 were not, along with 103 healthy controls. Crucially, the data came from one discovery cohort and two independent replication cohorts, allowing the researchers to test whether any patterns they found were stable across different groups of people rather than artifacts of a single sample. A longitudinal component followed 42 patients over time, providing a rare opportunity to see whether the brain-based subtypes tracked fluctuations in clinical suicide risk.

The analytical centerpiece of the study was a semi-supervised clustering-generative adversarial network, abbreviated Smile-GAN. Generative adversarial networks are machine learning architectures in which two neural networks compete: one generates candidate outputs while the other tries to distinguish them from real data. In this application, the framework was adapted to identify imaging-defined subtypes of dysconnectivity, using patients without suicidal thoughts and behaviors as the reference group against which anomalous connectivity patterns could be detected. This semi-supervised design means the model did not simply sort patients into arbitrary clusters; it specifically searched for patterns of brain connectivity that deviated from the non-suicidal reference state, a strategy well suited to a field where the boundaries between clinical categories are blurry and labels are often unreliable.

What emerged were two reproducible neurophysiological subtypes with strikingly different characteristics. The first was a visual cortex-predominant subtype, in which patients showed hyperconnectivity involving the visual cortex, the region at the back of the brain that processes incoming visual information. This pattern was associated with greater anxiety and poorer performance on tests of cognitive flexibility and working memory, including measures such as the Trail Making Test and the Digit Span Backward task. The second subtype was defined by hyperconnectivity between the default mode network and the central executive network, two large-scale brain systems that are normally engaged in a dynamic balance. The default mode network is active during self-referential thought and mind-wandering, while the central executive network governs goal-directed attention and control. Excessive coupling between these two networks was linked to brooding rumination, the repetitive, passive dwelling on negative feelings that is a well-established psychological risk factor for suicidal thinking.

The genetic findings added a layer of biological specificity to these imaging-defined groups. In the visual cortex-predominant subtype, the researchers constructed a genetic risk score from three single nucleotide polymorphisms in serotonergic genes: rs1631327 and rs6320 in HTR5A, which encodes the 5-hydroxytryptamine receptor 5A, and rs8066602 in SLC6A4, the gene for the serotonin transporter, a protein targeted by many antidepressant drugs. This three-variant score was associated with current-episode suicidal thoughts and behaviors within this subtype, and statistical mediation analysis showed that the effect was partially carried through right peripheral visual dysconnectivity. The mediated portion was 11.4 percent, with an effect size of 1.94 multiplied by ten to the power of minus two and a 95 percent confidence interval running from 1.08 multiplied by ten to the power of minus three to 0.05. In plain terms, a small but statistically detectable share of the genetic association with suicidal thinking appeared to operate by altering how visual brain circuits connect with the rest of the network.

The involvement of the serotonin system is scientifically coherent, since serotonergic signaling has been implicated in impulsivity, aggression, and suicide risk for decades, but the localization of the effect to visual cortex is more surprising and potentially important. It suggests that in some patients, inherited differences in serotonin biology may shape suicide-related vulnerability partly through sensory processing circuits rather than through the emotion and control networks that have traditionally dominated the literature. The researchers also examined transcriptomic and neurotransmitter maps from resources such as the Allen Human Brain Atlas to characterize the subtypes, situating the connectivity patterns within the broader molecular architecture of the cortex.

The default mode network-central executive network subtype carried its own genetic and clinical signal, this time in the treatment domain. In exploratory analyses, among carriers of the rs8066602 TC or TT genotypes who belonged to this subtype, patients with suicidal thoughts and behaviors showed greater symptom improvement after two weeks of treatment with pharmacotherapy and repetitive transcranial magnetic stimulation than comparable patients without suicidal thoughts and behaviors. The effect was substantial, with a beta coefficient of 31.01, a p value below 0.01, and a 95 percent confidence interval from 16.94 to 45.08. Repetitive transcranial magnetic stimulation, or rTMS, is a non-invasive brain stimulation technique that modulates cortical activity through magnetic pulses, and the finding hints that a patient’s imaging subtype and genetic background might eventually help predict who responds to which intervention.

Perhaps the most convincing evidence for the reality of these subtypes is their reproducibility. The subtype-specific dysconnectivity patterns replicated across the two independent cohorts, with correlation coefficients of 0.80 and 0.64 in the first replication sample and 0.65 and 0.73 in the second, all reaching adjusted p values below 0.001 on spatial permutation testing designed to account for the autocorrelated structure of brain maps. Moreover, in the longitudinal arm of the study, the strength of subtype-specific dysconnectivity covaried with fluctuations in individual suicide risk over time, suggesting that these are not static traits but dynamic markers that rise and fall with the clinical state. That combination of cross-cohort replication and within-person longitudinal tracking is exactly the kind of evidence that neuroimaging biomarkers have historically lacked.

The authors are careful to frame the genetic and treatment-related signals as preliminary. The genetic risk score rests on a small number of variants drawn from targeted sequencing of 61 suicide-related single nucleotide polymorphisms, and the treatment response analysis was exploratory, involving a limited number of patients followed for a short period. Prospective replication in larger, independently recruited samples will be needed before any of these findings can inform clinical decisions. The researchers also note that suicidal thoughts and behaviors in bipolar depression are profoundly heterogeneous, and that no single biomarker, genetic or neural, is likely to capture that complexity on its own. What this study offers instead is a framework: a way of stratifying patients into biologically meaningful groups before searching for predictors, rather than averaging across a mixed population and diluting the signals that matter.

If the findings hold up, the implications for suicide prevention could be significant. Clinicians currently lack reliable biological tools for assessing suicide risk, relying instead on self-report and clinical interview, both of which are vulnerable to concealment and fluctuation. A future in which a resting-state MRI scan, combined with a handful of genetic markers, could indicate whether a patient with bipolar depression falls into a visual-sensory risk profile or a rumination-linked network profile would open the door to subtype-informed stratification of risk and, eventually, to targeted interventions matched to each profile. The study also demonstrates the growing power of generative machine learning models in psychiatry, showing that adversarial architectures can extract reproducible structure from noisy, high-dimensional clinical data. For a field in which candidate biomarkers have repeatedly failed to replicate, the demonstration that two gene-brain-behavior profiles can survive independent testing and track clinical change over time is a noteworthy step toward making suicide risk assessment a genuinely biological science.

Subject of Research: Neurophysiological subtypes of suicide-related brain dysconnectivity in bipolar depression

Article Title: Gene-brain-behavior links revealing generative neurophysiological subtypes of suicide-related dysconnectivity in bipolar depression

Article References: Wang, T., Wei, X., Shen, N., Xia, Y., Dai, Z., Shao, J., Yan, R., Xiong, T., Tian, S., Yao, Z., Lu, Q., & Yao, Z. (2026). Gene-brain-behavior links revealing generative neurophysiological subtypes of suicide-related dysconnectivity in bipolar depression. BMC Medicine. https://doi.org/10.1186/s12916-026-05228-6

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05228-6

Keywords: bipolar depression, suicidal thoughts and behaviors, resting-state fMRI, generative adversarial network, brain connectivity, serotonin genes, HTR5A, SLC6A4, default mode network, transcranial magnetic stimulation, genetic risk score, psychiatry